Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GeroProtect

Financiado

Cerrado

Developing Geroprotectors to Prevent Polymorbidity

Advancing age is the major risk factor for disability and illness, including cardiovascular, metabolic and neu-rodegenerative disease and cancer. The increasing incidence of older people in European countries is posing major medic... ver más

30/11/2022

MPG

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-11-30

ERC-2016-ADG: ERC Advanced Grant

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

MPG

2.22M€ | Lider

EVERIS AEROESPACIAL Y DEFENS...

920.82K€ | Participante

Leiden University Medical Ce...

281.25K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-126280OB-I00 ACTIVACION DE CYB5R3 Y DE LA BIOSINTESIS DEL NAD+ COMO NUEVA... 169K€ Cerrado

PID2020-115189GB-I00 ENTENDIENDO EL IMPACTO DE LA UTILIZACION DE DOSIS SERIADAS D... 182K€ Cerrado

AgePhagy An integrated high throughput human cell and Drosophila scre... 150K€ Cerrado

MARRIAGE MARie CuRIe AGEing Network 4M€ Cerrado

PLATAFORMAS DE SCREENING MASIVO FARMACOLÓGICO... PLATAFORMAS DE SCREENING MASIVO FARMACOLÓGICO EN EL ÁREA DE... 1M€ Cerrado

HealthAge Joint Training and Research Program on Lifespan Regulation M... 4M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2017-11-09
Fecha Fin: 2022-11-30

Líder del proyecto

MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Advancing age is the major risk factor for disability and illness, including cardiovascular, metabolic and neu-rodegenerative disease and cancer. The increasing incidence of older people in European countries is posing major medical, social and economic challenges, and there is an urgent need to find ways of compressing late-life morbidity. Ageing has proved malleable to genetic and pharmacological interventions in laboratory animals, and at least some of the mechanisms are conserved over large evolutionary distances. Reduced activity of the nutrient-sensing insulin/insulin-like growth factor/TOR signalling network can increase health and combat ageing-related disease in laboratory animals, with increasing evidence of its importance in human ageing. There is thus a prospect for pharmacological intervention to prevent more than one ageing-related condition, rather than tackling diseases one by one and as they arise. The aim of this research programme is to evaluate the potential for pharmacological prevention of ageing-related decline in humans with a polypill targeting the nutrient-sensing network. We find that three licensed drugs, lithium, rapamycin and trametinib, act independently, at different nodes in the network, to increase lifespan in the fruitfly Drosophila, implying that the network controls more than one underlying mechanism of ageing, and that a polypill of these drugs could be particularly effective. We shall test this idea in mice, and assess the underlying mechanisms in Drosophila and mice. We have found that suppression of the Ras signalling branch of the network, which has a well known role in human cancer, can extend lifespan in both the fruitfly Drosophila and mice, and we shall assess its role in humans. Interventions that ameliorate ageing often have sex-specific effects, and we shall investigate the mechanisms leading to these for the nutrient-sensing network. The outputs of the work will inform future clinical trails in humans.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores